Literature DB >> 24811495

Fecal transplantation poses dilemma for FDA.

Mark Ratner.   

Abstract

Mesh：

Year:  2014        PMID： 24811495     DOI： 10.1038/nbt0514-401

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  3 in total

1.  Medicines from microbiota.

Authors:  Bernat Olle
Journal:  Nat Biotechnol       Date:  2013-04       Impact factor: 54.908

2.  The startup bugs.

Authors:  Charles Schmidt
Journal:  Nat Biotechnol       Date:  2013-04       Impact factor: 54.908

3.  Duodenal infusion of donor feces for recurrent Clostridium difficile.

Authors:  Els van Nood; Anne Vrieze; Max Nieuwdorp; Susana Fuentes; Erwin G Zoetendal; Willem M de Vos; Caroline E Visser; Ed J Kuijper; Joep F W M Bartelsman; Jan G P Tijssen; Peter Speelman; Marcel G W Dijkgraaf; Josbert J Keller
Journal:  N Engl J Med       Date:  2013-01-16       Impact factor: 91.245
  3 in total
  7 in total

1.  Microbial cocktails join fecal transplants in IBD treatment trials.

Authors:  Mark Ratner
Journal:  Nat Biotechnol       Date:  2015-08       Impact factor: 54.908

2.  Seres's pioneering microbiome drug fails mid-stage trial.

Authors:  Mark Ratner
Journal:  Nat Biotechnol       Date:  2016-10-11       Impact factor: 54.908

3.  OpenBiome remains open to serve the medical community.

Authors:  Mark Smith; Zain Kassam; Carolyn Edelstein; James Burgess; Eric Alm
Journal:  Nat Biotechnol       Date:  2014-09       Impact factor: 54.908

4.  Analysis of the microbiome: Advantages of whole genome shotgun versus 16S amplicon sequencing.

Authors:  Ravi Ranjan; Asha Rani; Ahmed Metwally; Halvor S McGee; David L Perkins
Journal:  Biochem Biophys Res Commun       Date:  2015-12-22       Impact factor: 3.575

Review 5.  The human intestinal microbiome at extreme ages of life. Dietary intervention as a way to counteract alterations.

Authors:  Nuria Salazar; Silvia Arboleya; Lorena Valdés; Catherine Stanton; Paul Ross; Lorena Ruiz; Miguel Gueimonde; Clara G de Los Reyes-Gavilán
Journal:  Front Genet       Date:  2014-11-21       Impact factor: 4.599

Review 6.  Clinical translation of microbe-based therapies: Current clinical landscape and preclinical outlook.

Authors:  Ava M Vargason; Aaron C Anselmo
Journal:  Bioeng Transl Med       Date:  2018-07-06

Review 7.  Clostridium difficile drug pipeline: challenges in discovery and development of new agents.

Authors:  Angie M Jarrad; Tomislav Karoli; Mark A T Blaskovich; Dena Lyras; Matthew A Cooper
Journal:  J Med Chem       Date:  2015-03-30       Impact factor: 7.446
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.